Agilent (California, USA) has formed a co-marketing agreement with Molecular Discovery Ltd (Perugia, Italy).
Agilent (California, USA) has formed a co-marketing agreement with Molecular Discovery Ltd (Perugia, Italy). The agreement will result in the provision of an advanced metabolite-identification platform to researchers, bridging the gap between metabolite analysis software and hardware in research laboratories.
Metabolite analysis using liquid chromatography–mass spectroscopy (LC–MS) is central to the discovery of new drugs, allowing scientists insight into the mechanisms of disease. Many regulatory agencies require that metabolite testing be carried out prior to the initiation of human clinical trials, in order to determine the potential adverse effects of the drug tested on human metabolism. This is considered to be expensive and time-consuming, therefore is generally left until the final stages of preclinical testing. This co-marketing agreement has the potential to reduce the time required for this stage of testing, by combining software and hardware technologies and thereby removing incompatibility issues.
“Until now, the challenges of identifying and predicting human drug metabolism have been major obstacles in the development of safe, effective drug candidates,” said Gus Salem, the vice president and general manager of Agilent’s Biological Systems Division. “Together, Agilent Technologies and Molecular Discovery are working to solve this problem in pharmaceutical research. Whereas traditional metabolite identification, synthesis and toxicity testing has been costly and time-consuming for researchers, our combined industry-leading technologies will now give them faster, more accurate data, and the confidence they need to ensure the safety of their products much earlier in the preclinical phase of development.”
For more information please visit:
ref=http://www.agilent.com> www.agilent.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Investigating Synthetic Cathinone Positional Isomers using LC–EAD-MS
November 7th 2024Peng Che fom Vrije Universiteit Amsterdam in the Netherlands discusses the benefits of hyphenating liquid chromatography (LC) with electron activated dissociation mass spectrometry (EAD-MS) to analyze cathinone positional isomers.